Literature DB >> 9025730

Fatty acid metabolic imaging with iodine-123-BMIPP for the diagnosis of coronary artery disease.

S Fujiwara1, Y Takeishi, H Atsumi, K Takahashi, H Tomoike.   

Abstract

UNLABELLED: Iodine-123-BMIPP kinetics under high glucose levels were examined. The feasibility of 123I-BMIPP imaging after oral glucose loading for the detection of impaired fatty acid metabolism was tested in patients with coronary artery disease.
METHODS: Fatty acid metabolic imaging with 123I-BMIPP was performed on 29 patients in the fasting state and repeated after oral glucose loading. Myocardial SPECT images were obtained 20 min and 4 hr after the injection of 123I-BMIPP. Myocardial uptake of 123I-BMIPP was calculated by a Ishii-Macintyre method and the clearance of 123I-BMIPP from the myocardium was determined as (early counts-delayed counts) x 100/early counts. Regional accumulation of 123I-BMIPP was scored semiquantitatively from 0 (normal) to 4 (no activity), and the sum of regional scores in each patient was defined as a total defect score (TDS).
RESULTS: Total myocardial uptake of 123I-BMIPP was 1.7% +/- 0.4% in the fasting state and 1.6% +/- 0.3% after oral glucose loading (p < 0.05). Iodine-123-BMIPP clearance from the myocardium was faster after glucose loading than in the fasting state (27% +/- 8% versus 11% +/- 6%, p < 0.01). After glucose loading, 123I-BMIPP clearance was faster in the ischemic myocardium (defined as areas perfused by stenosed coronary artery exceeding 90%) than in the nonischemic myocardium (33% +/- 8% versus 25% +/- 9%, p < 0.05). TDS in the ischemic myocardium increased from 1.8 +/- 0.4 in the fasting state to 2.1 +/- 0.4 after glucose loading (p < 0.01). The sensitivity for detecting coronary stenosis exceeding 90% increased from 55% (11/20) in the fasting state to 75% (15/20) after glucose loading without a loss of specificity (78%, 7/9).
CONCLUSION: Oral glucose loading enhanced the detection of areas with impaired fatty acid metabolism due to coronary artery narrowing. Iodine-123-BMIPP imaging with oral glucose loading may be a new approach for the noninvasive diagnosis of coronary artery disease.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9025730

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  14 in total

1.  Perfusion-BMIPP mismatch: specific finding or artifact?

Authors:  Koichi Morita; Eriko Tsukamoto; Nagara Tamaki
Journal:  Int J Cardiovasc Imaging       Date:  2002-08       Impact factor: 2.357

2.  Is BMIPP a sensitive marker for myocardial ischaemic stress? For.

Authors:  Nagara Tamaki; Koichi Morita
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-05-27       Impact factor: 9.236

Review 3.  Diagnostic and prognostic value of BMIPP imaging.

Authors:  Taishiro Chikamori; Akira Yamashina; Satoshi Hida; Tsunehiko Nishimura
Journal:  J Nucl Cardiol       Date:  2007-01       Impact factor: 5.952

Review 4.  The Japanese experience with metabolic imaging in the clinical setting.

Authors:  Nagara Tamaki; Koichi Morita; Yuko Kawai
Journal:  J Nucl Cardiol       Date:  2007 May-Jun       Impact factor: 5.952

5.  Prediction of functional recovery in acute myocardial infarction: comparison between sestamibi reverse redistribution and sestamibi/BMIPP mismatch.

Authors:  S Fujiwara; Y Takeishi; H Atsumi; M Yamaki; N Takahashi; M Yamaoka; T Tojo; H Tomoike
Journal:  J Nucl Cardiol       Date:  1998 Mar-Apr       Impact factor: 5.952

Review 6.  Ischaemic memory imaging using metabolic radiopharmaceuticals: overview of clinical settings and ongoing investigations.

Authors:  Keiichiro Yoshinaga; Masanao Naya; Tohru Shiga; Eriko Suzuki; Nagara Tamaki
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-11-12       Impact factor: 9.236

7.  Myocardial metabolism of 123I-BMIPP under low-dose dobutamine infusion: implications for clinical SPECT imaging of ischemic heart disease.

Authors:  Ryohei Hosokawa; Ryuji Nohara; Taku Hirai; Yasuhisa Fujibayashi; Masatoshi Fujita; Naoshige Kambara; Muneo Ohba; Eiji Tadamura; Takeshi Kimura; Toru Kita
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-08-21       Impact factor: 9.236

8.  Clinical utility of myocardial fatty acid imaging in patients with end-stage renal disease.

Authors:  Masato Nishimura; Toshihiko Ono
Journal:  J Nucl Cardiol       Date:  2008-09-16       Impact factor: 5.952

9.  Enhanced washout of 99mTc-tetrofosmin in hypertrophic cardiomyopathy: quantitative comparisons with regional 123I-BMIPP uptake and wall thickness determined by MRI.

Authors:  Tohoru Takeda; Jin Wu; Yuko Fumikura; Keiji Iida; Satoru Kawano; Iwao Yamaguchi; Yuji Itai
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-05-20       Impact factor: 9.236

Review 10.  Diagnostic accuracy of beta-methyl-p-[123I]-iodophenyl-pentadecanoic acid (BMIPP) imaging: a meta-analysis.

Authors:  Yoichi Inaba; Steven R Bergmann
Journal:  J Nucl Cardiol       Date:  2008-04-16       Impact factor: 5.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.